Atlanta, GA, United States

Morehouse School of Medicine

www.msm.edu
Atlanta, GA, United States

Morehouse School of Medicine is a medical school in Atlanta, Georgia, USA. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Morehouse School of Medicine | Date: 2017-03-30

This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.


Patent
Morehouse School of Medicine | Date: 2017-01-03

The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.


Patent
Morehouse School of Medicine | Date: 2017-02-28

This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.


Patent
Morehouse School of Medicine | Date: 2016-12-13

A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.


Patent
The Uab Research Foundation, University of Oregon, University of Cardiff and Morehouse School of Medicine | Date: 2016-11-21

Described herein are nitrated lipids and methods of making and using the nitrated lipids.


Patent
The Uab Research Foundation, University of Oregon, University of Cardiff and Morehouse School of Medicine | Date: 2016-02-10

Described herein are nitrated lipids and methods of making and using the nitrated lipids.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 315.32K | Year: 2015

DESCRIPTION provided by applicant The most common metastatic site for hormone refractory prostate cancer HRPC PCa is bone While docetaxel can prolong the overall survival in patients with metastatic HRPC current treatments do not provide a cure Further complicating the matter HRPC is a disease that affects a variety of patients differently which can be problematic for physicians to provide standardized treatments with similar outcomes African Americans AAs with HRPC can experience significantly lower rates of overall survival faster rates of tumor progression and poor responses to chemotherapy than compared to European Americans EAs with this disease Unfortunately the mechanisms behind these PCa health disparities have not been well studied To address these issues investigators at Morehouse School of Medicine and JYANT Technologies Inc have identified a critical pathway that controls PCa cell growth metastasis to bone and docetaxel response rates the CXCL CXCR axis We previously reported the functional expression of CXCR by PCa cell lines and that CXCL the only ligand for CXCR can mediate PCa cell growth migration invasion and docetaxel resistance In addition we reported significantly higher CXCR expression by prostate tumors from patients with advance PCa than compared to normal matched or benign disease tissues Our exciting preliminary data show CXCR expression by prostate tumors resected from AA patients are significantly as much as two fold higher than EAs with the same disease stage Previously we demonstrated serum CXCL levels are significantly higher in PCa patients and this ligand is secreted by bone marrow endothelium under conditions found during this disease Finally we show that our murine anti human CXCL antibody both prevented and shrunk HRPC xenografts established in femurs of SCID mice In consideration of these findings JYANT Technologies seeks to develop a novel humanized anti human CXCL monoclonal antibody CXCL HuMAB for the treatment of HRPC and to address the disparities in clinical and therapeutic outcomes with this disease To complete these objectives we will use clinically relevant mouse models of osteolytic and osteoblastic HRPC as well as docetaxel resistant xenografts to carry out the following aims Aim One will ascertain the immunogenicity using na ve B mice and the PK PD profile of CXCL HuMAB in SCID mice bearing luciferase expressing osteolytic PC luc and osteoblastic C b luc xenografts in femurs Aim Two will determine the systemic and immune toxicity as well as the efficacy of CXCL HuMAB to inhibit prostate tumor growth and docetaxel resistance in bone using SCID mice challenged in femurs with hormone refractory PC luc and C b luc and or docetaxel resistant PC R luc and C bR luc PCa cell lines PUBLIC HEALTH RELEVANCE To date there is no cure for metastatic HRPC chemoresistance toxicities and variable response rates hinder the use of many drugs e g docetaxel to treat PCa Using clinically relevant HRPC models this study tests the utility of targeting the CXCL CXCR axis which is highly elevated in AAs than compared to EAs with HRPC


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 225.00K | Year: 2015

DESCRIPTION provided by applicant Triple negative breast cancer TNBC is very difficult to treat and has no specific targeted therapies Chemotherapies used to treat this disease have many undesirable side effects and patients eventually relapse as a result of chemoresistance Obesity is pandemic in the US and many TNBC suffer from this as well Obesity is accompanied by high levels of leptin and is linked to the highest mortality rates in TNBC patients In contrast to normal mammary cells TNBC cells overexpress the leptin receptor and significantly proliferate under leptin interactions Our exciting findings suggest leptin is involved in TNBC acquired drug resistance through the induction of breast cancer stem cells BCSC Anti angiogenic drugs show limited success for TNBC but these shortcomings could be due in part to angiogenic signal redundancy i e leptin JYANT Technologies Inc has designed a proprietary potent and highly specific inhibitor of leptin signaling leptin peptide receptor antagonist LPrA The peptide conjugated to polyethylene glycol kDa PEG wLPrA has a hour half life after intravenous administration and significantly reduces TNBC growth Preliminary data also show that PEG wLPrA does not induce changes in food intake body weight or general health status We propose the use of PEG wLPrA as an adjuvant therapy for TNBC that will improve the efficacy and reduce dosage and toxicities associated with current TNBC therapy e g doxorubicin cyclophosphamide paclitaxel PEG wLPrA will target leptinandapos s proliferative pro angiogenic and BCSC related actions in TNBC This study will evaluate this novel adjuvant therapy in clinically relevant obesity TNBC models Specifically toxicity an adjuvant therapy studies along with doxorubicin cyclophosphamide and or paclitaxel treatments will be carried out in lean and obese mice hosting human and mouse TNBC xenografts and syngeneic grafts The experimental data generated from this STTR Phase I proposal will allow for the rapid translation of an innovative and targeted adjuvant therapy for TNBC This novel strategy will generate an effective therapy for reducing chemoresistance relapse and metastasis of TNBC via depletion BCSC which are maintained by leptin signaling Our proposed studies are of paramount importance for TNBC sufferers especially those that are overweight or obese which shows the highest levels of leptin and TNBC incidence PUBLIC HEALTH RELEVANCE Biunivocal binding affinity activation and oncogenic effects of leptin leptin receptor complex in breast cancer cells makes it a novel molecular target for the treatment of triple negative breast cancer TNBC particularly in the context of obesity The proposed project will test a novel adjuvant therapeutic PEG wLPrA which will significantly impact current TNBC therapy by reducing dosage side effects and improve efficacy


Patent
Morehouse School of Medicine | Date: 2016-05-27

A system, including methods and compositions, for treatment of ischemia.


Patent
Morehouse School of Medicine | Date: 2016-02-19

This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.

Loading Morehouse School of Medicine collaborators
Loading Morehouse School of Medicine collaborators